Ponatinib as targeted therapy for FGFR1 fusions associated with the 8p11 myeloproliferative syndrome
Andrew Chase(Wessex Regional Genetics Laboratory), Nicholas C.P. Cross(University of Southampton)
Cited by 71
Related Papers
Clinical and biological implications of driver mutations in myelodysplastic syndromes
|Blood|2013|1.8k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Somatic<i>SF3B1</i>Mutation in Myelodysplasia with Ring Sideroblasts
|New England Journal of Medicine|2011|1.2k
Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia
|Journal of Clinical Oncology|2013|543
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements
|Haematologica|2012|35